Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.

Responses to -targeted therapy are generally temporary, due to inevitable drug resistance. The prevalence and characteristics of receptor tyrosine-kinase (RTK) fusion as acquired resistance to EGFR tyrosine-kinase inhibitors (TKIs) are rarely investigated. We retrospectively reviewed genomic profiling data of 3873 (exons 18-21)-mutant lung cancer patients with more than once next-generation sequencing detection. A total of 16 patients who acquired RTK fusions during EGFR-TKI treatment with paired pre- and post-EGFR-TKI samples were identified. Their treatment history was collected. Newly acquired RTK fusions during EGFR-TKI treatment included (n=6, 37.5%), (n=5, 31.3%), (n=4, 25.0%), (n=1, 6.3%), and (n=1, 6.3%). All and - fusions were uncommon variants of and E2:A20 (V5), respectively. Interestingly, fusion occurred only after osimertinib treatment, and contributed to drug resistance in 50% (6 of 12) of patients treated with osimertinib, indicating that fusions had different prevalence when functioning as resistance mechanisms to EGFR TKIs. Moreover, we found that in all patients developing drug resistance to EGFR TKIs due to fusion emergence (n=16), those that had a treatment history of third-generation EGFR TKIs accounted for 75% (n=12). We have extended the current knowledge of resistance mechanisms to EGFR TKIs in non-small-cell lung cancer. Detection of RTK fusions should be included in genomic profiling panels to uncover potential resistance mechanisms of EGFR TKIs, which might inform therapeutic strategies, such as combination-therapy approaches, to circumvent tumorigenesis.